Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Santarus expects more Zegerid approvals

This article was originally published in The Tan Sheet

Executive Summary

Other markets will approve the proton pump inhibitor in 2010, predicts Santarus CEO Gerald Proehl. "We may start to see some modest royalties in the last part of 2010 and into 2011" from GlaxoSmithKline, Proehl said Dec. 15 at the Lippert/Heilshorn Life Sciences Virtual Conference. GSK licenses Zegerid (omeprazole/sodium bicarbonate) in 114 countries in Africa, Asia, the Middle East and Central and South America (1"The Tan Sheet" June 2, 2008). Santarus licensed Rx and OTC Zegerid in Europe to U.K. pharma Norgine in October. Proehl said he also anticipates sales milestone payments as Merck/Schering-Plough introduces Zegerid OTC in U.S. in the first half of 2010 (2"The Tan Sheet" Dec. 7, 2009)

You may also be interested in...

Zegerid OTC Approved, Limited To Touting Dual-Ingredient Formula For Now

Merck's Schering-Plough Consumer HealthCare Products division will launchZegerid OTC in the first half of 2010 as the first dual-ingredient OTC proton pump inhibitor

Zegerid Switch Progress Generates Bottom Line Help For Santarus

Santarus' OTC licensing of its Zegerid Rx heartburn remedy to Schering-Plough has yet to pay dividends for S-P, but the deal is already helping Santarus reduce its net loss

What’s Next? Five Things To Look Out For In April

Generics Bulletin previews the biggest events and changes for industry in the coming month.


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts